Идёт набор NCT07300150

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Фаза I С лечением Colorectal Cancer Pancreatic Cancer Non-Small Cell Lung Cancer Solid Tumor

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: PT0511, Cetuximab.
Кому может быть актуально: Состояния в реестре: Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, South Korea
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Phase 1, Open-label Dose Escalation and Expansion Study Of PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors

Обзор

The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).

Вмешательства

Препарат PT0511
Intravenous infusion.
Препарат Cetuximab
Intravenous infusion.

Первичные конечные точки

Number of Participants with Dose-limiting Toxicities (DLT) [Срок оценки: Cycle 1 (Cycle length=21 days)]
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) [Срок оценки: Up to 24 months]
Number of Participants with TEAEs Leading to Treatment Interruptions, Dose Reductions and Permanent Discontinuations [Срок оценки: Up to 24 months]

Вторичные конечные точки (12)

Cmax/C0: Maximum Blood Concentration (Cmax) and/or Concentration at Time 0 (C0) of PT0511 [Срок оценки: Cycle 1 Days 1 and 15: Pre-infusion and up to 24 hours post-infusion (Cycle length=21 days)]
Tmax: Time to Reach Cmax of PT0511 [Срок оценки: Cycle 1 Days 1 and 15: Pre-infusion and up to 24 hours post-infusion (Cycle length=21 days)]
AUC0-t: Area Under the Curve From time 0 to the time of the Last Quantifiable Concentration of PT0511 [Срок оценки: Cycle 1 Days 1 and 15: Pre-infusion and up to 24 hours post-infusion (Cycle length=21 days)]
t1/2: Terminal Elimination Half-life of PT0511 [Срок оценки: Cycle 1 Days 1 and 15: Pre-infusion and up to 24 hours post-infusion (Cycle length=21 days)]
AUC0-∞: Area Under the Curve From Time 0 Extrapolated to Infinity of PT0511 [Срок оценки: Cycle 1 Days 1 and 15: Pre-infusion and up to 24 hours post-infusion (Cycle length=21 days)]
CL: Clearance of PT0511 [Срок оценки: Cycle 1 Days 1 and 15: Pre-infusion and up to 24 hours post-infusion (Cycle length=21 days)]
Vd: Volume of Distribution of PT0511 [Срок оценки: Cycle 1 Days 1 and 15: Pre-infusion and up to 24 hours post-infusion (Cycle length=21 days)]
Overall Response Rate (ORR) [Срок оценки: Up to 12 months]
Duration of Response (DOR) [Срок оценки: Up to 12 months]
Number of Participants with Antitumor Activity Markers in Peripheral Blood of PT0511 [Срок оценки: Cycle 1 Day 15: Pre-infusion and up to 24 hours post-infusion (Cycle length=21 days)]
Overall Survival (OS) [Срок оценки: At 1 year]
Progression-free Survival (PFS) [Срок оценки: At 1 year]

Критерии участия

Критерии включения

Men or women less than or equal to (>=) 18 years of age
Histologically or cytologically confirmed advanced or metastatic solid malignancy
Participant has a pathologically documented, locally advanced or metastatic malignancy with any KRAS mutation or wild-type (WT) KRAS amplification identified through molecular testing using a Clinical Laboratory Improvement Amendments (CLIA) certified, validated institutional or commercial test
Participant must have received at least 1 and no more than 4 prior systemic therapies or be intolerant or ineligible for available therapies known to provide clinical benefit
Measurable disease (RECIST 1.1 Criteria)
ECOG Performance Status 0 or 1
Willingness to avoid pregnancy or fathering children screening through 90 days after the last dose of study treatment

Критерии исключения

Cancer History

Active brain metastasis or carcinomatous meningitis. If participants have had brain metastases resected or have received radiation therapy, they may be eligible if: (1) study treatment begins at least 4 weeks from the end of brain-specific therapy, (2) residual neurological symptoms Grade <=2, (3) currently on stable doses of corticosteroids, and (4) pre-study brain MRI documents no new/worsening brain lesions
History of any other malignancy within the past 2 years, except:

Malignancy treated with curative intent and with no known active disease present >=2 years before enrolment and felt to be at low risk for recurrence by the investigator
Basal or squamous cell carcinoma of the skin, in situ cervical cancer, early -stage endometrial cancer that has been definitively treated, superficial bladder cancer, Gleason 6/7 treated prostate cancer, and ductal carcinoma in situ or lobular carcinoma in situ of the breast

Prior Cancer Therapy

Unresolved toxicities from prior anti-cancer therapies. Participants with prior endocrine replacement therapies are eligible for entry even if administered to treat endocrine deficiency due to the prior anti-cancer therapy
Concurrent participation in another interventional clinical study.
Treatment with anticancer medications or investigational drugs within the following intervals before the first administration of study drug:

At least 14 days for chemotherapy or targeted small-molecule therapy
At least 28 days for a prior monoclonal antibody
At least 28 days or 5 half-lives (whichever is longer) for all other investigational study drugs or devices. For drugs with very long half-lives, participants may be allowed to enroll prior to 5 half-lives at the discretion of the investigator in discussion with the medical monitor
Note: Concurrent hormonal therapy for prostate or breast cancer is allowable
Prior treatment with a KRAS/RAS degrader

Medical History

Significant cardiovascular disease within 6 months of starting study therapy
Active infection requiring antibiotics within 7 days of study treatment.
Known HIV infection with a CD4+ T-cell count <200 cells/mcL and/or a detectable viral load per parameters of assay and/or on an anti-retroviral regimen containing a strong or moderate CYP3A4/5 inhibitor or inducer and/or on a new anti-retroviral regimen for less than 28 days prior to the initiation of study treatment
Known history of drug-induced liver injury; primary biliary cirrhosis; or ongoing extrahepatic obstruction caused by stones, cirrhosis of the liver, or portal hypertension
Major surgery within 4 weeks of the start of study therapy or postoperative complications preventing the participant from adhering to protocol assessments and procedures
Known hypersensitivity to any of the products to be administered during dosing
Any disease or disorder that, in the opinion of the investigator, may compromise the ability of the participant to provide written informed consent and/or to comply with all required study procedures

Medications

Part 1a (Dose escalation): Use of a strong or moderate CYP3A4/5 inhibitor or inducer, Use of a strong P-gp inhibitor or inducer

Organ Function

Participants with laboratory values indicating inadequate hematology, hepatic, or renal function

Diagnostic Assessments

Clinically significant abnormalities in rhythm, conduction, or morphology of resting ECG
Baseline QT interval corrected for heart rate using Fridericia's formula (QTcF) >=470 msec
Female participants of childbearing age with a positive urine or serum test within 7 days of study start or confirmation from Ob/Gyn that any positive bHCG test is not representative of an ongoing pregnancy
Women who are lactating/breast feeding or who plan to breastfeed while on study through 28 days after receiving the last dose of study drug
Active HBV infection. Participants with resolved infection or who are on Stable antiviral therapy are eligible
Active HCV infection. Participants who have completed definitive antiviral therapy with post treatment confirmation of eradication are eligible

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет